Follow
Bruno Catalanotti
Title
Cited by
Cited by
Year
Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors
L Savini, A Gaeta, C Fattorusso, B Catalanotti, G Campiani, L Chiasserini, ...
Journal of Medicinal Chemistry 46 (1), 1-4, 2003
1842003
Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives
G Campiani, A Ramunno, G Maga, V Nacci, C Fattorusso, B Catalanotti, ...
Current pharmaceutical design 8 (8), 615-657, 2002
1632002
Synthesis and Pharmacological Evaluation of Potent and Highly Selective D3 Receptor Ligands:  Inhibition of Cocaine-Seeking Behavior and the Role of Dopamine D3/D …
G Campiani, S Butini, F Trotta, C Fattorusso, B Catalanotti, F Aiello, ...
Journal of medicinal chemistry 46 (18), 3822-3839, 2003
1152003
Hijacking SARS-CoV-2/ACE2 receptor interaction by natural and semi-synthetic steroidal agents acting on functional pockets on the receptor binding domain
A Carino, F Moraca, B Fiorillo, S Marchianò, V Sepe, M Biagioli, ...
Frontiers in Chemistry 8, 572885, 2020
1032020
Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of …
G Campiani, C Fattorusso, S Butini, A Gaeta, M Agnusdei, S Gemma, ...
Journal of medicinal chemistry 48 (6), 1919-1929, 2005
902005
Endoperoxide derivatives from marine organisms: 1, 2-dioxanes of the plakortin family as novel antimalarial agents
C Fattorusso, G Campiani, B Catalanotti, M Persico, N Basilico, S Parapini, ...
Journal of medicinal chemistry 49 (24), 7088-7094, 2006
802006
Pyrrolo [1, 3] benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure− activity relationship studies, and identification of …
G Campiani, S Butini, C Fattorusso, B Catalanotti, S Gemma, V Nacci, ...
Journal of medicinal chemistry 47 (1), 143-157, 2004
792004
Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors
S Butini, G Campiani, M Borriello, S Gemma, A Panico, M Persico, ...
Journal of medicinal chemistry 51 (11), 3154-3170, 2008
692008
Neuronal high-affinity sodium-dependent glutamate transporters (EAATs): targets for the development of novel therapeutics against neurodegenerative diseases
G Campiani, C Fattorusso, M Angelis, B Catalanotti, S Butini, R Fattorusso, ...
Current pharmaceutical design 9 (8), 599-625, 2003
682003
A rational approach to the design of selective substrates and potent nontransportable inhibitors of the excitatory amino acid transporter EAAC1 (EAAT3). New glutamate and …
G Campiani, M De Angelis, S Armaroli, C Fattorusso, B Catalanotti, ...
Journal of medicinal chemistry 44 (16), 2507-2510, 2001
652001
Discovery of Huperzine A− Tacrine Hybrids as Potent Inhibitors of Human Cholinesterases Targeting Their Midgorge Recognition Sites
S Gemma, E Gabellieri, P Huleatt, C Fattorusso, M Borriello, B Catalanotti, ...
Journal of medicinal chemistry 49 (11), 3421-3425, 2006
632006
Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad …
C Fattorusso, S Gemma, S Butini, P Huleatt, B Catalanotti, M Persico, ...
Journal of medicinal chemistry 48 (23), 7153-7165, 2005
612005
Benzoxepin-derived estrogen receptor modulators: a novel molecular scaffold for the estrogen receptor
DG Lloyd, RB Hughes, DM Zisterer, DC Williams, C Fattorusso, ...
Journal of medicinal chemistry 47 (23), 5612-5615, 2004
582004
Pyrrolo [1, 5] benzoxa (thia) zepines as a new class of potent apoptotic agents. Biological studies and identification of an intracellular location of their drug target
MM Mc Gee, S Gemma, S Butini, A Ramunno, DM Zisterer, C Fattorusso, ...
Journal of medicinal chemistry 48 (13), 4367-4377, 2005
542005
Exploitation of a very small peptide nucleic acid as a new inhibitor of miR‐509‐3p involved in the regulation of cystic fibrosis disease‐gene expression
F Amato, R Tomaiuolo, F Nici, N Borbone, A Elce, B Catalanotti, ...
BioMed research international 2014 (1), 610718, 2014
532014
Design and synthesis of potent antimalarial agents based on clotrimazole scaffold: exploring an innovative pharmacophore
S Gemma, G Campiani, S Butini, G Kukreja, BP Joshi, M Persico, ...
Journal of medicinal chemistry 50 (4), 595-598, 2007
502007
Pyrrolo [1, 3] benzothiazepine-based atypical antipsychotic agents. Synthesis, structure− activity relationship, molecular modeling, and biological studies
G Campiani, S Butini, S Gemma, V Nacci, C Fattorusso, B Catalanotti, ...
Journal of medicinal chemistry 45 (2), 344-359, 2002
482002
Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies
G Campiani, S Butini, C Fattorusso, F Trotta, S Gemma, B Catalanotti, ...
Journal of medicinal chemistry 48 (6), 1705-1708, 2005
472005
Specific Targeting of Peripheral Serotonin 5-HT3 Receptors. Synthesis, Biological Investigation, and Structure−Activity Relationships
E Morelli, S Gemma, R Budriesi, G Campiani, E Novellino, C Fattorusso, ...
Journal of medicinal chemistry 52 (11), 3548-3562, 2009
462009
Insight into the mechanism of action of plakortins, simple 1, 2-dioxane antimalarials
O Taglialatela-Scafati, E Fattorusso, A Romano, F Scala, V Barone, ...
Organic & Biomolecular Chemistry 8 (4), 846-856, 2010
452010
The system can't perform the operation now. Try again later.
Articles 1–20